Patents by Inventor Masakazu Hatano
Masakazu Hatano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8232308Abstract: A method for treating a disease in which Rho kinase is involved. The method is carried out by administering to a patient in need thereof a pharmaceutically effective amount of a compound of the following formula or a pharmaceutically acceptable salt thereof: wherein the ring X is a benzene ring or a pyridine ring; R1 and R2 are hydrogen or alkyl or together form a cycloalkene ring; R3 is hydrogen, substituted alkyl, unsubstituted alkenyl, carboxyl or an ester or an amide thereof, amino or a cyano; R4 is hydrogen, hydroxyl, substituted or unsubstituted alkoxy, unsubstituted alkenyloxy, unsubstituted cycloalkyloxy substituted or unsubstituted alkyl, unsubstituted alkenyl, unsubstituted cycloalkyl, amino, substituted or unsubstituted alkylamino, nitro, cyano or a monocyclic heterocycle; and R5 is a halogen atom or a hydrogen atom.Type: GrantFiled: October 20, 2010Date of Patent: July 31, 2012Assignees: UBE Industries, Ltd., Santen Pharmaceutical Co., Ltd.Inventors: Masahiko Hagihara, Ken-ichi Komori, Hidetoshi Sunamoto, Hiroshi Nishida, Takeshi Matsugi, Tadashi Nakajima, Masakazu Hatano, Kazutaka Kido, Hideaki Hara
-
Publication number: 20110263638Abstract: A therapeutic agent for glaucoma including a combination of pharmaceutically effective amounts of a Rho kinase inhibitor and a ?-blocker, wherein the Rho kinase inhibitor is (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide and the ?-blocker is befunolol, carteolol, nipradilol, betaxolol, levobunolol or metipranolol. A method of treating glaucoma including administering effective amounts of a Rho kinase inhibitor and a ?-blocker to a patient, wherein the Rho kinase inhibitor is (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide and the ?-blocker is befunolol, carteolol, nipradilol, betaxolol, levobunolol or metipranolol.Type: ApplicationFiled: June 30, 2011Publication date: October 27, 2011Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Masakazu Hatano, Tadashi Nakajima, Takeshi Matsugi, Hideaki Hara
-
Patent number: 7972612Abstract: A subject of the present invention is to find utility of a combination of a Rho kinase inhibitor having a novel action and a ?-blocker as a therapeutic agent for glaucoma. Actions of reducing intraocular pressure are complemented and/or enhanced each other by combining the Rho kinase inhibitor with the ?-blocker. For the administration mode, each drug can be administered in combination or in mixture.Type: GrantFiled: November 17, 2003Date of Patent: July 5, 2011Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Masakazu Hatano, Tadashi Nakajima, Takeshi Matsugi, Hideaki Hara
-
Publication number: 20110039891Abstract: A method for treating a disease in which Rho kinase is involved. The method is carried out by administering to a patient in need thereof a pharmaceutically effective amount of a compound of the following formula or a pharmaceutically acceptable salt thereof: wherein the ring X is a benzene ring or a pyridine ring; R1 and R2 are hydrogen or alkyl or together form a cycloalkene ring; R3 is hydrogen, substituted alkyl, unsubstituted alkenyl, carboxyl or an ester or an amide thereof, amino or a cyano; R4 is hydrogen, hydroxyl, substituted or unsubstituted alkoxy, unsubstituted alkenyloxy, unsubstituted cycloalkyloxy substituted or unsubstituted alkyl, unsubstituted alkenyl, unsubstituted cycloalkyl, amino, substituted or unsubstituted alkylamino, nitro, cyano or a monocyclic heterocycle; and R5 is a halogen atom or a hydrogen atom.Type: ApplicationFiled: October 20, 2010Publication date: February 17, 2011Applicants: UBE INDUSTRIES, LTD., SANTEN PHARMACEUTICAL CO., LTD.Inventors: Masahiko Hagihara, Ken-ichi Komori, Hidetoshi Sunamoto, Hiroshi Nishida, Takeshi Matsugi, Tadashi Nakajima, Masakazu Hatano, Kazutaka Kido, Hideaki Hara
-
Patent number: 7855222Abstract: A method for treating a disease in which Rho kinase is involved. The method is carried out by administering to a patient in need thereof a pharmaceutically effective amount of a compound of the following formula or a pharmaceutically acceptable salt thereof: wherein the ring X is a benzene ring or a pyridine ring; R1 and R2 are hydrogen or alkyl or together form a cycloalkene ring; R3 is hydrogen, substituted alkyl, unsubstituted alkenyl, carboxyl or an ester or an amide thereof, amino or a cyano; R4 is hydrogen, hydroxyl, substituted or unsubstituted alkoxy, unsubstituted alkenyloxy, unsubstituted cycloalkyloxy, substituted or unsubstituted alkyl, unsubstituted alkenyl, unsubstituted cycloalkyl, amino, substituted or unsubstituted alkylamino, nitro, cyano or a monocyclic heterocycle; and R5 is a halogen atom or a hydrogen atom.Type: GrantFiled: June 19, 2009Date of Patent: December 21, 2010Assignees: UBE Industries, Ltd., Santen Pharmaceutical Co., Ltd.Inventors: Masahiko Hagihara, Ken-ichi Komori, Hidetoshi Sunamoto, Hiroshi Nishida, Takeshi Matsugi, Tadashi Nakajima, Masakazu Hatano, Kazutaka Kido, Hideaki Hara
-
Publication number: 20090264468Abstract: A method for treating a disease in which Rho kinase is involved. The method is carried out by administering to a patient in need thereof a pharmaceutically effective amount of a compound of the following formula or a pharmaceutically acceptable salt thereof: , wherein the ring X is a benzene ring or a pyridine ring; R1 and R2 are hydrogen or alkyl or together form a cycloalkene ring; R3 is hydrogen, substituted alkyl, unsubstituted alkenyl, carboxyl or an ester or an amide thereof, amino or a cyano; R4 is hydrogen, hydroxyl, substituted or unsubstituted alkoxy, unsubstituted alkenyloxy, unsubstituted cycloalkyloxy, substituted or unsubstituted alkyl, unsubstituted alkenyl, unsubstituted cycloalkyl, amino, substituted or unsubstituted alkylamino, nitro, cyano or a monocyclic heterocycle; and R5 is a halogen atom or a hydrogen atom.Type: ApplicationFiled: June 19, 2009Publication date: October 22, 2009Applicants: UBE INDUSTRIES, LTD., SANTEN PHARMACEUTICALS CO., LTD.Inventors: Masahiko Hagihara, Ken-ichi Komori, Hidetoshi Sunamoto, Hiroshi Nishida, Takeshi Matsugi, Tadashi Nakajima, Masakazu Hatano, Kazutaka Kido, Hideaki Hara
-
Patent number: 7563906Abstract: An object of the present invention is to create a novel indazole derivative useful as a drug and to find a novel pharmacological action of the derivative. The compound of the present invention is represented by the formula [I] and has an excellent Rho kinase inhibiting action. In the formula, a ring X is a benzene ring or a pyridine ring; R1 and R2 are H or alkyl; R3 and R4 are halogen, H, OH, alkoxy, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, aryloxy, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, carboxy, hydrocarbonyl, alkylcarbonyl, etc.; and R5 is halogen atom, H, OH, alkoxy, aryloxy, alkyl or aryl. Each group can be substituted.Type: GrantFiled: October 15, 2004Date of Patent: July 21, 2009Assignees: Ube Industries, Ltd., Santen Pharmaceutical Co., Ltd.Inventors: Masahiko Hagihara, Ken-ichi Komori, Hidetoshi Sunamoto, Hiroshi Nishida, Takeshi Matsugi, Tadashi Nakajima, Masakazu Hatano, Kazutaka Kido, Hideaki Hara
-
Publication number: 20070129404Abstract: An object of the present invention is to create a novel indazole derivative useful as a drug and to find a novel pharmacological action of the derivative. The compound of the present invention is represented by the formula [I] and has an excellent Rho kinase inhibiting action. In the formula, a ring X is a benzene ring or a pyridine ring; R1 and R2 are H or alkyl; R3 and R4 are halogen, H, OH, alkoxy, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, aryloxy, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, carboxy, hydrocarbonyl, alkylcarbonyl, etc.; and R5 is halogen atom, H, OH, alkoxy, aryloxy, alkyl or aryl. Each group can be substituted.Type: ApplicationFiled: October 15, 2004Publication date: June 7, 2007Inventors: Masahiko Hagihara, Ken-ichi Komori, Hidetoshi Sunamoto, Hiroshi Nishida, Takeshi Matsugi, Tadashi Nakajima, Masakazu Hatano, Kazutaka Kido, Hideaki Hara
-
Publication number: 20060052367Abstract: A subject of the present invention is to find utility of a combination of a Rho kinase inhibitor having a novel action and a ?-blocker as a therapeutic agent for glaucoma. Actions of reducing intraocular pressure are complemented and/or enhanced each other by combining the Rho kinase inhibitor with the ?-blocker. For the administration mode, each drug can be administered in combination or in mixture.Type: ApplicationFiled: November 17, 2003Publication date: March 9, 2006Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Masakazu Hatano, Tadashi Nakajima, Takeshi Matsugi, Hideaki Hara